Next-generation antibody platform

Our proprietary antibody discovery platform is a core strength upon which we continue to build and improve. Leveraging this platform, we are able to identify rare and broad antibodies with enhanced selectivity and potency using artificial intelligence-led protein engineering.

Specifically, we leverage dAIsy^TM (data AI structure and antibody), our proprietary artificial intelligence engine, which allows us to bring high-quality drug candidates to the clinic more efficiently. dAIsY uses a mix of open source and proprietary tools that run in parallel, allowing us to fine tune multiple desirable antibody characteristics simultaneously, ultimately generating a lead antibody with the highest potential for development success.  

The platform has already yielded two commercial medicines, sotrovimab¹ for COVID-19, which was developed in just 15 months, and ansuvimab-zykl for Ebola, which has been recognized by the World Health Organization for its impact.

To learn more about diseases we are targeting using our monoclonal antibody platform, click here.

¹ GSK holds a marketing authorization for sotrovimab in the EU, Norway, Iceland, Bahrain, Great Britain (conditional), and Switzerland (conditional). In Japan, a Special Approval in Emergency has been granted. In addition, sotrovimab has a temporary/emergency use authorization in the UAE and Oman.